Li-Yu Hu1, Fan-Chen Ku2, Ti Lu3, Cheng-Che Shen4, Yu-Wen Hu5, Chiu-Mei Yeh6, Cheng-Hwai Tzeng7, Tzeng-Ji Chen8, Pan-Ming Chen9, Chia-Jen Liu10. 1. Department of Psychiatry, Kaohsiung Veterans General Veterans Hospital, Kaohsiung, Taiwan; Institute of Public Health, School of Medicine, National Yang-Ming University, Taipei, Taiwan. 2. Division of Hematology and Medical Oncology, Department of Medicine, Changhua Show-Chwan Memorial Hospital, Changhua, Taiwan. 3. Department of Psychiatry, Kaohsiung Veterans General Veterans Hospital, Kaohsiung, Taiwan. 4. Department of Psychiatry, Chiayi Branch, Taichung Veterans General Hospital, Chiayi, Taiwan. 5. Institute of Public Health, School of Medicine, National Yang-Ming University, Taipei, Taiwan; Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan. 6. Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 7. Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan. 8. Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan. 9. Department of Psychiatry, Yuanshan Branch, Taipei Veterans General Hospital, Yilan, Taiwan. 10. Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Public Health, School of Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address: chiajenliu@gmail.com.
Abstract
PURPOSE: The aim of our study was to evaluate the overall cancer risk among patients with the irritable bowel syndrome (IBS) by using a nationwide population-based data set. METHODS: We obtained data on newly diagnosed IBS patients (age ≥ 20 years) without antecedent cancer from the Taiwan National Health Insurance Research Database for the period between 2000 and 2010. Standardized incidence ratios (SIRs) were calculated for various types of cancer in the IBS patients. RESULTS: A total of 1,043 people among the 29,838 IBS patients had developed cancer, and the follow-up was 139,185 person-years (median, 4.56 years), leading to a significantly increased SIR (1.18; 95% confidence interval [CI]) = 1.11-1.26) among all cancer types. However, after excluding cancer that developed within the first year after IBS diagnosis, the increased SIR of overall cancer was nonsignificant. In particular, the IBS patients exhibited an increased risk of cancers of the colon and rectum (SIR = 1.51; 95% CI = 1.31-1.73), liver and biliary tract (SIR = 1.40; 95% CI = 1.21-1.62), pancreas (SIR = 1.56; 95% CI = 1.02-2.28), and kidney (SIR = 1.56; 95% CI = 1.10-2.15). CONCLUSIONS: An increased SIR in IBS patients was observed only within the first year of IBS diagnosis. The findings of this study might have resulted from detection bias, localized symptoms, or paraneoplastic syndromes associated with IBS-like symptoms. Additional prospective studies are necessary to confirm these findings.
PURPOSE: The aim of our study was to evaluate the overall cancer risk among patients with the irritable bowel syndrome (IBS) by using a nationwide population-based data set. METHODS: We obtained data on newly diagnosed IBSpatients (age ≥ 20 years) without antecedent cancer from the Taiwan National Health Insurance Research Database for the period between 2000 and 2010. Standardized incidence ratios (SIRs) were calculated for various types of cancer in the IBSpatients. RESULTS: A total of 1,043 people among the 29,838 IBSpatients had developed cancer, and the follow-up was 139,185 person-years (median, 4.56 years), leading to a significantly increased SIR (1.18; 95% confidence interval [CI]) = 1.11-1.26) among all cancer types. However, after excluding cancer that developed within the first year after IBS diagnosis, the increased SIR of overall cancer was nonsignificant. In particular, the IBSpatients exhibited an increased risk of cancers of the colon and rectum (SIR = 1.51; 95% CI = 1.31-1.73), liver and biliary tract (SIR = 1.40; 95% CI = 1.21-1.62), pancreas (SIR = 1.56; 95% CI = 1.02-2.28), and kidney (SIR = 1.56; 95% CI = 1.10-2.15). CONCLUSIONS: An increased SIR in IBSpatients was observed only within the first year of IBS diagnosis. The findings of this study might have resulted from detection bias, localized symptoms, or paraneoplastic syndromes associated with IBS-like symptoms. Additional prospective studies are necessary to confirm these findings.
Authors: Kyle Staller; Ola Olén; Jonas Söderling; Bjorn Roelstraete; Hans Törnblom; Hamed Khalili; Mingyang Song; Jonas F Ludvigsson Journal: Eur J Intern Med Date: 2021-08-20 Impact factor: 4.487
Authors: Sven H Loosen; Markus S Jördens; Mark Luedde; Dominik P Modest; Simon Labuhn; Tom Luedde; Karel Kostev; Christoph Roderburg Journal: J Clin Med Date: 2021-12-16 Impact factor: 4.241